drugset / Trial / NCT07527039

Pectoral Block in Breast Reduction for Pain Control

NCT07527039

Phase 4 Recruiting 80 enrolled Carilion Clinic
RandomizedParallel-groupSingle-blindSupportive care

Summary

A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap indentation. It is well documented in the literature that this procedure has a statistically significant reduction in patient symptoms. Postoperatively, it has been within the norm to prescribe narcotics in order to alleviate post-procedural pain. Recently, however, the research realm has advocated a non-narcotic multimodal pain control (MMPC) approach to minimize narcotic usage. Narcotic use is associated with increased costs in the healthcare system due to reported heightened pain scores for extended duration, constipation, nausea, vomiting, opiate dependence among other factors associated with increased morbidity. The goal of this study is to determine if PECs II (pectoral block type II) block alone is non-inferior to the standard multimodal pain control with narcotics for postoperative pain reduction in breast reduction.

Timeline

Start
2026-04-01
Primary completion
2028-05
Completion
2028-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 5 mg Oral
Subject Oxycodone Other / unclassified 10 mg Oral
Background Acetaminophen Small molecule 1000 mg
Background Ibuprofen Small molecule 600 mg

Indications